Tao Xia, Hu Wei, Ramirez Pedro T, Kavanagh John J
Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S67-71. doi: 10.1016/j.ygyno.2008.04.024. Epub 2008 Jun 3.
Our purpose is to review the chemotherapy for recurrent and metastatic cervical cancer.
We reviewed the phase II and III clinical trials of chemotherapy regimens and recent advances of targeted therapy for treatment of recurrent and metastatic cervical cancer. We also reviewed chemotherapy for rare histological subtypes of cervical cancer.
Recent data has shown that the combination of cisplatinum and topotecan is the only regimen to demonstrate a progression-free survival and overall survival advantage over single agent cisplatin in the setting of recurrent cervical cancer. Preliminary study results indicate that targeted therapies may have an important role in the management of recurrent or metastatic cervical cancer.
There remains a need for novel agents and further research focusing on the management of recurrent and metastatic cervical cancer. Future goals of therapy are to increase efficacy of treatment options while decreasing toxicity.
我们的目的是回顾复发性和转移性宫颈癌的化疗情况。
我们回顾了用于治疗复发性和转移性宫颈癌的化疗方案的II期和III期临床试验以及靶向治疗的最新进展。我们还回顾了宫颈癌罕见组织学亚型的化疗情况。
近期数据表明，在复发性宫颈癌的治疗中，顺铂与拓扑替康联合使用是唯一一种相较于单药顺铂能显示出无进展生存期和总生存期优势的方案。初步研究结果表明，靶向治疗可能在复发性或转移性宫颈癌的管理中发挥重要作用。
仍需要新型药物以及针对复发性和转移性宫颈癌管理的进一步研究。未来的治疗目标是提高治疗方案的疗效同时降低毒性。
